BridgeBio Pharma, Inc. (BBIO) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Attributable Net Product Revenue (Atruvi) | 180.6M | FY2026-Q1 |
| License and Service Revenue | 4.4M | FY2026-Q1 |
| Royalty Revenue | 9.5M | FY2026-Q1 |
| Average Reduction in Serum Creatine Kinase (CK) Change from Baseline (Twelve Months) | 82.00 percent | FY2026-Q1 |
| Glycosylated Alpha-Dystroglycan (Alpha DG) Change from Baseline (Three Months) | 1.80 ratio | FY2026-Q1 |
| Unique Patient Prescriptions for Attruby (Cumulative since FDA Approval) | 5.26K | FY2025-Q3 |
| Unique Prescribers for Attruby (Cumulative since FDA Approval) | 1.36K | FY2025-Q3 |
| Net Product Revenue (Attruby) (First Full Quarter Post-Launch) | 36.7M | FY2025-Q1 |
Back to BBIO overview · BBIO earnings · BBIO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.